ArticleSignal transduction and targeted therapy2024
LIM-domain-only 4 (LMO4) enhances CD8
Abstract read
In one paragraph
Article in Signal transduction and targeted therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Overcoming T cell exhaustion and senescence in CAR T cell therapy for solid tumors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- High-Content CRISPR Screening: Methods and Applications.MedComm · 2026Review
- Article
- Role of the STAT3 Signaling Pathway in Cell Proliferation and Inflammation in Psoriasis and Approaches for Targeted Therapies: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2026Review
- STAT3 signaling in cancer: mechanisms and targeting therapeutic.Frontiers in immunology · 2026Review
- Impact of IL-21 on CAR T-cell manufacturing: phenotypic, metabolic, and functional outcomes.Frontiers in immunology · 2026Article
- Gene transfer and genome editing of T cells for cancer immunotherapy: from allogeneic HSCT to TCR gene editing.Hematology. American Society of Hematology. Education Program · 2025Review
- LMO4 promotes OSCC progression by inducing RAB17 degradation and ferroptosis resistance.Cell death & disease · 2025Article
- Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy.Molecular cancer · 2025Review
- Review
- Article
- Interleukin-21 engineering enhances CD19-specific CAR-NK cell activity against B-cell lymphoma via enriched metabolic pathways.Experimental hematology & oncology · 2025Article
- Highlighting recent achievements to advance more effective cancer immunotherapy.Journal of experimental & clinical cancer research : CR · 2025Article
- Effect of adipocytes on the function and activity of T cells in tumor microenvironment.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Roland C SchelkerDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany. roland.schelker@ukr.de.
Jessica FioravantiDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.ORCID 0000-0001-6263-4306
Fabio MastrogiovanniDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Jeremy G BaldwinDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Nisha RanaDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Peng LiLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Ping ChenCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Timea VadászDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Rosanne SpolskiLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Christoph Heuser-LoyDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.ORCID 0000-0003-1410-7573
Dragana Slavkovic-LukicDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.ORCID 0000-0002-3107-7727
Pedro NoronhaDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Giuseppe DamianoImmuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, IRCCS Scientific Institute San Raffaele, Milan, Italy.
Laura RaccostaImmuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, IRCCS Scientific Institute San Raffaele, Milan, Italy.
Daniela MaggioniImmuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, IRCCS Scientific Institute San Raffaele, Milan, Italy.
Sree PullugulaLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Jian-Xin LinLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-5849-9412
Jangsuk OhLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Patrick GrandinettiCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Mario LecceDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Leo HesseDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Emilia KocksDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Azucena Martín-SantosDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.
Claudia GebhardNext Generation Sequencing Core, Leibniz Institute for Immunotherapy, Regensburg, Germany.
William G TelfordCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Yun JiCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Nicholas P RestifoCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Vincenzo RussoImmuno-Biotherapy of Melanoma and Solid Tumors Unit, Division of Experimental Oncology, IRCCS Scientific Institute San Raffaele, Milan, Italy.
Michael RehliDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Wolfgang HerrDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Warren J Leonard *Laboratory of Molecular Immunology and the Immunology Center, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. leonardw@nhlbi.nih.gov.ORCID 0000-0002-5740-7448
Luca Gattinoni *Division of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany. luca.gattinoni@lit.eu.ORCID 0000-0003-2239-3282
Funding
IL-2 Family Cytokines and their Receptors-- Biology of the IL-21 systemZIAHL005408 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI LEONARD, WARREN J · 2009 to 2025
$23.7MFACS Core FacilityZICBC011138 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI TELFORD, WILLIAM · 2009 to 2025
$14.5MAssociazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG 22737Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG 26305
Abstract
High frequencies of stem-like memory T cells in infusion products correlate with superior patient outcomes across multiple T cell therapy trials. Herein, we analyzed a published CRISPR activation screening to identify transcriptional regulators that could be harnessed to augment stem-like behavior in CD8
Indexed as
Adaptor Proteins, Signal TransducingCD8-Positive T-LymphocytesLIM Domain ProteinsSignal TransductionSTAT3 Transcription FactorAnimalsCell DifferentiationHumansInterleukinsMiceAdaptor Proteins, Signal TransducingInterleukinsLIM Domain ProteinsSTAT3 protein, humanSTAT3 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.